What do systematic reviews say?

Silodosin vs placebo

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 820 participants
  Moderate

Silodosin vs alfuzosin

Silodosin probably leads to higher sexual adverse events compared with alfuzosin (moderate certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 37.21 [5.32, 260.07]
  1 study · 95 participants
  Moderate

Silodosin vs placebo

Silodosin showed no clear difference in treatment withdrawal due to any reason compared with placebo (low certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 1.08 [0.7, 1.66]
  3 studies · 1703 participants
  Low

Silodosin vs placebo

It is very uncertain whether silodosin changes cardiovascular adverse events compared with placebo (very low certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 1.28 [0.67, 2.45]
  4 studies · 1967 participants
  Very low

Silodosin vs placebo

Silodosin probably leads to higher sexual adverse events compared with placebo (moderate certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 26.07 [12.36, 54.97]
  4 studies · 1967 participants
  Moderate

Silodosin vs tamsulosin

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 1708 participants
  Low

Silodosin vs tamsulosin

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 1707 participants
  Low

Silodosin vs tamsulosin

It is very uncertain whether silodosin changes treatment withdrawal due to any reason compared with tamsulosin (very low certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 1.02 [0.62, 1.69]
  10 studies · 1573 participants
  Very low

Silodosin vs tamsulosin

Silodosin showed no clear difference in cardiovascular adverse events compared with tamsulosin (low certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 0.77 [0.53, 1.12]
  11 studies · 1955 participants
  Low

Surgical vs non‐surgical treatment

• Surgery versus non‐surgical management for unilateral ureteric‐pelvic junction obstruction in newborns and infants… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 17 participants
  Very low

Surgical vs non‐surgical treatment

• Surgery versus non‐surgical management for unilateral ureteric‐pelvic junction obstruction in newborns and infants… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 57 participants
  Very low

Surgical vs non‐surgical treatment

• Surgery versus non‐surgical management for unilateral ureteric‐pelvic junction obstruction in newborns and infants… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 15 participants
  Very low

Surgical vs non‐surgical treatment

• Surgery versus non‐surgical management for unilateral ureteric‐pelvic junction obstruction in newborns and infants… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Non‐steroidal antiandrogen monotherapy vs LHRH agonists or surgical castration monotherapy

Non‐steroidal antiandrogen monotherapy probably leads to higher overall survival compared with LHRH agonists or surgical castration monotherapy (moderate certainty).

• Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical… 2014 · Cochrane Headline outcomes only
  HR 1.24 [1.05, 1.48]
  6 studies · 2712 participants
  Moderate

Non‐steroidal antiandrogen monotherapy vs LHRH agonists or surgical castration monotherapy

Non‐steroidal antiandrogen monotherapy probably leads to higher clinical progression compared with LHRH agonists or surgical castration monotherapy (moderate certainty).

• Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical… 2014 · Cochrane Headline outcomes only
  RR 1.26 [1.08, 1.45]
  6 studies · 2373 participants
  Moderate

Non‐steroidal antiandrogen monotherapy vs LHRH agonists or surgical castration monotherapy

Non‐steroidal antiandrogen monotherapy probably leads to higher treatment failure compared with LHRH agonists or surgical castration monotherapy (moderate certainty).

• Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical… 2014 · Cochrane Headline outcomes only
  RR 1.27 [1.05, 1.52]
  5 studies · 1845 participants
  Moderate

Non‐steroidal antiandrogen monotherapy vs LHRH agonists or surgical castration monotherapy

Non‐steroidal antiandrogen monotherapy probably leads to higher breast pain compared with LHRH agonists or surgical castration monotherapy (moderate certainty).

• Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical… 2014 · Cochrane Headline outcomes only
  RR 22.97 [14.79, 35.67]
  8 studies · 2670 participants
  Moderate

Non‐steroidal antiandrogen monotherapy vs LHRH agonists or surgical castration monotherapy

Non‐steroidal antiandrogen monotherapy probably leads to higher gynaecomastia compared with LHRH agonists or surgical castration monotherapy (moderate certainty).

• Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical… 2014 · Cochrane Headline outcomes only
  RR 8.43 [3.19, 22.28]
  9 studies · 2774 participants
  Moderate

Non‐steroidal antiandrogen monotherapy vs LHRH agonists or surgical castration monotherapy

Non‐steroidal antiandrogen monotherapy probably leads to lower hot flashes compared with LHRH agonists or surgical castration monotherapy (moderate certainty).

• Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical… 2014 · Cochrane Headline outcomes only
  RR 0.23 [0.19, 0.27]
  9 studies · 2774 participants
  Moderate

Intervention not reported

The review found no eligible studies for this question.

• Screening for prostate cancer 2013 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found